Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Negative 70.0%

Neg 70% Neu 0% Pos 0%

Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform and maintains $40 price target.